Amplia Therapeutics Limited
Clinical trials sponsored by Amplia Therapeutics Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to boost Chemotherapy's punch against pancreatic cancer Results expected Feb 2027 (estimated)
-
New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
Disease control OngoingThis trial tests whether adding an experimental drug called AMP945 to standard chemotherapy (nab-paclitaxel and gemcitabine) can improve tumor shrinkage in people with advanced pancreatic cancer that cannot be removed by surgery. The study has two parts: first, finding the best d…
Phase 1/2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo shows promise in tough pancreatic cancer
Disease control OngoingThis study tests a new drug called narmafotinib, taken as a daily pill, together with a standard chemotherapy regimen (mFOLFIRINOX) in people whose pancreatic cancer has spread. The trial has two parts: first, finding a safe dose, then comparing two doses in 20 people each. The g…
Phase 1/2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC